[HTML][HTML] The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a …
N Fukuda, N Horita, S Katakura… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related
death worldwide. There is a rank order of the efficacy and safety of treatment options …
death worldwide. There is a rank order of the efficacy and safety of treatment options …
Impact of bevacizumab versus erlotinib on tumor metrics in patients with previously untreated advanced non-small cell lung cancer: a study by the hellenic cooperative …
G Mountzios, X Mavropoulou, GA Koliou… - Anticancer …, 2020 - ar.iiarjournals.org
Background: The mechanism of action of bevacizumab and erlotinib is quite different in the
treatment of advanced non-small cell lung cancer (NSCLC). This study sought to compare …
treatment of advanced non-small cell lung cancer (NSCLC). This study sought to compare …
[HTML][HTML] Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature
C Zhang, X Wang, M Zhang, D Liu, DP Yang - Medicine, 2020 - journals.lww.com
Interventions: The patient had received 4 months of neoadjuvant therapy using oral apatinib
(425 mg daily) plus S-1 (60 mg, twice daily for 4 weeks with a 2-week drug-free interval) …
(425 mg daily) plus S-1 (60 mg, twice daily for 4 weeks with a 2-week drug-free interval) …
[HTML][HTML] Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
E Cusano, C Wong, E Taguedong, M Vaska, T Abedin… - Current …, 2021 - mdpi.com
In the era of rapid development of new, expensive cancer therapies, value frameworks have
been developed to quantify clinical benefit (CB). We assessed the evolution of CB since the …
been developed to quantify clinical benefit (CB). We assessed the evolution of CB since the …